Fatty acid oxidation inhibitor and its role in management of angina pectoris

Alakhras, Mohammad Adnan Mohammad
Folyóirat címe
Folyóirat ISSN
Kötet címe (évfolyam száma)
Fatty acid oxidation inhibitors showed in the recent researches the effect on controlling of many cardiac diseases and here I’m going to spot on the effect of the fatty acid oxidation inhibitors in the management of angina pectoris, since angina pectoris has an estimated prevalence of 4.6 million in women and 3.3 million in men. Fatty acid oxidation inhibitors can play their role and inhibit fatty acid oxidation in many different ways by example the direct inhibitors of fatty acid oxidation are Trimrtazidine and Ranolazine, drugs are working at the level of the carnitine palmitoyltransferase ( CPT-1) inhibitors by example Etomoxir, Oxfenicine and Perhexiline and other drugs working on inhibition of carnitine biosynthesis by example mildronate. Fatty acid oxidation inhibitors are doing their function by decreasing the amount of the oxygen required by decreasing the heart rate, contractility and due to that the cardiac work will be less. Fatty acid oxidation inhibitors also have an important vulnerable effect on angina patient with maximum dose of the other angina drugs by example calcium channel blocker or beta blocker but still symptomatic. Other than this those drugs are increasing the mechanical efficacy of the left ventricle without hemodynamic disturbances.
fatty acid oxidation inhibitor